| Group 1 (HPV-positive) (SLE patients = 15) | Group 2 (HPV-negative) (SLE patients = 31) |
---|---|---|
Clinical features | Â | Â |
   SLE duration, mean ± S.D.(range), year | 18 ± 8 (6 to 36) | 13 ± 6 (5 to 28) †|
   SLICC, median (IQR) | 1 (0 to 2) | 0 (0 to 1) |
   SLEDAI score, median (IQR) | 2 (0 to 6) | 2 (0 to 4) |
Serological features | Â | Â |
   Serum complement C3, median (IQR), g/l | 0.9 (0.7 to 1.1) | 0.8 (0.6 to 1.0) |
   Serum complement C4, median (IQR), g/l | 0.2 (0.1 to 0.3) | 0.2 (0.1 to 0.3) |
   Elevated anti-dsDNA (> 100 IU/ml) | 6 (40) | 13 (42) |
   Anti-dsDNA titer, median (IQR), IU/ml | 308 (210 to 591) | 331 (93 to 572) |
Major organ involvement ever | Â | Â |
   0 | 0 (0) | 3 (10) |
   1 | 1 (7) | 9 (29) |
   ≥ 2 | 14 (93) | 19 (61) †|
   Neuropsychiatric | 3 (20) | 10 (32) |
   Nephritis | 12 (80) | 17 (55) |
   Serositis | 6 (40) | 7 (23) |
   Hematologic | 15 (100) | 24 (77) †|
Immunosuppressive therapy ever | 15 (100) | 29 (94) |
   Prednisolone | 14 (93) | 24 (77) |
   Hydroxychloroquine | 12 (80) | 15 (48) †|
   Azathioprine | 9 (60) | 16 (52) |
   Cyclophosphamide (oral or IV) | 2 (13) | 5 (16) |
   Cyclosporin A | 2 (13) | 7 (23) |
   Mycophenolate mofetil | 3 (20) | 5 (16) |